[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MAP3K1

Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00069 Protein kinase domain
Function

Component of a protein kinase signal transduction cascade (PubMed:9808624). Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624). May phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173). Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway (PubMed:9808624).

> Gene Ontology
 
Biological Process GO:0000186 activation of MAPKK activity
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0009612 response to mechanical stimulus
GO:0031349 positive regulation of defense response
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0043405 regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045860 positive regulation of protein kinase activity
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071496 cellular response to external stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004709 MAP kinase kinase kinase activity
GO:0005057 receptor signaling protein activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04120 Ubiquitin mediated proteolysis
hsa04530 Tight junction
hsa04622 RIG-I-like receptor signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04912 GnRH signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166058: MyD88
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAP3K1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAP3K1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAP3K1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5550.125
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9940.508
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2360.832
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3980.15
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.490.819
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2860.92
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0010.998
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.310.864
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2890.882
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5550.631
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0330.527
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0810.352
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAP3K1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAP3K1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAP3K1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAP3K1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAP3K1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAP3K1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAP3K1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAP3K1
Namemitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
Aliases MEKK; MAPKKK1; MEKK1; mitogen-activated protein kinase kinase kinase 1; MEKK 1; SRXY6; MAP/ERK kinase kinase ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAP3K1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MAP3K1.
ID Name Drug Type Targets #Targets
DB06061AZD-8330Small MoleculeMAP3K11